CN114929219A - 使用整联蛋白抑制剂组合治疗肝脏疾病 - Google Patents

使用整联蛋白抑制剂组合治疗肝脏疾病 Download PDF

Info

Publication number
CN114929219A
CN114929219A CN202080088263.6A CN202080088263A CN114929219A CN 114929219 A CN114929219 A CN 114929219A CN 202080088263 A CN202080088263 A CN 202080088263A CN 114929219 A CN114929219 A CN 114929219A
Authority
CN
China
Prior art keywords
liver
disorder
liver disease
pharmaceutical combination
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080088263.6A
Other languages
English (en)
Chinese (zh)
Inventor
K·安德森
C·贝利
A·博斯
J·查
N·库珀
D·芬克尔斯坦
L·格林鲍姆
J·赫尔
S·科克兰德
K·莱夫特里斯
M·莱利
P·塔尔萨
C·乌科马达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Pliant Therapeutics Inc
Original Assignee
Novartis AG
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Pliant Therapeutics Inc filed Critical Novartis AG
Publication of CN114929219A publication Critical patent/CN114929219A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080088263.6A 2019-12-20 2020-12-18 使用整联蛋白抑制剂组合治疗肝脏疾病 Pending CN114929219A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951615P 2019-12-20 2019-12-20
US62/951,615 2019-12-20
PCT/US2020/066079 WO2021127483A1 (en) 2019-12-20 2020-12-18 Combination treatment of liver diseases using integrin inhibitors

Publications (1)

Publication Number Publication Date
CN114929219A true CN114929219A (zh) 2022-08-19

Family

ID=74186956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080088263.6A Pending CN114929219A (zh) 2019-12-20 2020-12-18 使用整联蛋白抑制剂组合治疗肝脏疾病

Country Status (11)

Country Link
US (1) US20230055657A1 (enExample)
EP (1) EP4076455A1 (enExample)
JP (1) JP2023507387A (enExample)
KR (1) KR20220121838A (enExample)
CN (1) CN114929219A (enExample)
AR (1) AR120859A1 (enExample)
AU (1) AU2020405182B2 (enExample)
CA (1) CA3165000A1 (enExample)
IL (1) IL293895A (enExample)
TW (1) TW202135812A (enExample)
WO (1) WO2021127483A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220220206A1 (en) * 2019-05-20 2022-07-14 Mayo Foundation For Medical Education And Research Treating chronic liver disease
US20230060422A1 (en) * 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049068A1 (en) * 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
RU2019110780A (ru) * 2016-09-14 2020-10-15 Новартис Аг Комбинация агонистов fxr
TWI841573B (zh) * 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN118852054A (zh) * 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049068A1 (en) * 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHAUB JOHANNA ET AL:: "PS091-Targeted disruption of TGF-B activation by an AVB1 integrin inhibitor significantly reduces liver fibrosis in CCl4 mice and human NASH liver slices"", KNEE SURGERY, SPORTS TRAUMATOLOGY, ARTHROSCOPY, 1 May 2019 (2019-05-01) *

Also Published As

Publication number Publication date
AU2020405182B2 (en) 2024-03-14
EP4076455A1 (en) 2022-10-26
CA3165000A1 (en) 2021-06-24
JP2023507387A (ja) 2023-02-22
AU2020405182A1 (en) 2022-07-07
IL293895A (en) 2022-08-01
KR20220121838A (ko) 2022-09-01
US20230055657A1 (en) 2023-02-23
TW202135812A (zh) 2021-10-01
AR120859A1 (es) 2022-03-23
WO2021127483A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
RU2737324C2 (ru) Способы применения агонистов fxr
JP6986022B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
TW202438513A (zh) 用於治療與體重增加相關之疾病或病症之愛帕琳(apelin)受體促效劑及glp-1受體促效劑之組合療法
US20210283105A1 (en) Novel regimes of fxr agonists
AU2020201980A1 (en) Combination of FXR agonists
US20200276178A1 (en) Combinations comprising fxr agonists
CN114929218A (zh) 使用整联蛋白抑制剂组合治疗肝脏疾病
CN114929219A (zh) 使用整联蛋白抑制剂组合治疗肝脏疾病

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220819